TransCode Therapeutics (RNAZ)
(Delayed Data from NSDQ)
$10.39 USD
-0.26 (-2.44%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $10.69 +0.30 (2.89%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RNAZ 10.39 -0.26(-2.44%)
Will RNAZ be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RNAZ based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RNAZ
All You Need to Know About TransCode Therapeutics (RNAZ) Rating Upgrade to Buy
RNAZ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for RNAZ
12 Health Care Stocks Moving In Wednesday's Intraday Session
RNAZ Trading Temporarily Halted Due to Volatility Pause | RNAZ Stock News
Transcode Therapeutics (RNAZ) Resumes Trading Activity | RNAZ Stock News
Transcode Therapeutics Inc trading resumes
Transcode Therapeutics Inc trading halted, volatility trading pause